# AstraZeneca’s Capivasertib could become first-in-class treatment option for HR-positive breast cancer

- Link: https://www.directorstalkinterviews.com/astrazenecas-capivasertib-could-become-first-in-class-treatment-option-for-hr-positive-breast-cancer/4121088149
- Published: 2022-10-26T07:42:16+01:00
- Author: Amilia Stone

Positive high-level results from the CAPItello-291 Phase III trial showed that **
[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
capivasertib in combination with _Faslodex_ (fulvestrant) demonstrated a statistically
significant and clinically meaningful improvement in progression-free survival (
PFS) versus placebo plus _Faslodex_ in patients with hormone receptor (HR)-positive,
human epidermal growth factor receptor 2 (HER2)-low or negative locally advanced
or metastatic breast cancer, following recurrence or progression on or after endocrine
therapy (with or without a CDK4/6 inhibitor).

The trial met both primary endpoints, improving PFS in the overall patient population
and in a prespecified biomarker subgroup of patients whose tumours had qualifying
alterations in the PIK3CA, AKT1 or PTEN genes. Although the overall survival (OS)
data were immature at the time of the analysis, early data are encouraging. The 
trial will continue to assess OS as a key secondary endpoint.

The safety profile of capivasertib plus _Faslodex_ was similar to that observed 
in previous trials evaluating this combination.

Breast cancer is the most common cancer worldwide, with an estimated 2.3 million
patients diagnosed in 2020.^(1) Approximately 70% of breast cancer tumours are considered
HR-positive and HER2-low or negative.^(2) Endocrine therapies are widely used for
the treatment of HR-positive breast cancer, but many patients with advanced disease
develop resistance to 1st-line CDK4/6 inhibitors and estrogen receptor-targeting
therapies, underscoring the need for additional options.^(3)

> **Nicholas Turner, MD, PhD, Professor of Molecular Oncology at The Institute of
> Cancer Research, London, and The Royal Marsden NHS Foundation Trust, London, UK,
> and principal investigator in the CAPItello-291 Phase III trial, said: **“The 
> CAPItello-291 Phase III trial results show capivasertib offers a clinically meaningful
> improvement in progression free survival for patients with HR-positive breast 
> cancer. This potential new medicine could give people more time with their cancer
> under control, which is a priority for patients and their families.”

> **Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said**:“
> These exciting data in an all-comers population indicate that capivasertib could
> become a new first-in-class treatment option for patients with HR-positive breast
> cancer. These patients often experience tumour progression on, or resistance to,
> available endocrine therapies for advanced disease and urgently need new therapies
> that extend the effectiveness of endocrine-based treatment approaches.”

The data will be presented at a forthcoming medical meeting and shared with global
health authorities.

AstraZeneca has a comprehensive portfolio of approved and potential new medicines
in development for patients with breast cancer. In addition to these results, the
Company is also announcing today results from the SERENA-2 Phase II trial of camizestrant,
the next-generation oral selective estrogen receptor degrader (ngSERD) in advanced
estrogen receptor (ER)-positive breast cancer.

Share on:
